Drug Repurposing of Loratadine As a DNMT1 Inhibitor: Comparative Evaluation With Cisplatin in Patient-Derived Oral Squamous Cell Carcinoma Cells. Precis. Med. Com. 2024, 4 (2), 125-137. https://doi.org/10.55627/pmc.004.02.1083.